Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

ECU Author/Contributor (non-ECU co-authors, if there are any, appear on document)

Stephen L. Abrams (Creator)

Jörg Bäsecke (Creator)

Marco Donia (Creator)

Paolo Fagone (Creator)

Richard A. Franklin (Creator)

Ruth C. Kempf (Creator)

Massimo Libra (Creator)

Maksimovic-Iva Libra (Creator)

Jacquelyn M. Long (Creator)

Graziella Malaponte (Creator)

Maria C. Mazzarino (Creator)

Ferdinando Nicoletti (Creator)

Franca Stivala (Creator)

Agostino Tafuri (Creator)

Institution

East Carolina University (ECU )

Web Site: http://www.ecu.edu/lib/

Abstract: Extracted text; The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK). Integral components of these pathways, Ras, B-Raf, PI3K, and PTEN are also activated/inactivated by mutations. These pathways have profound effects on proliferative, apoptotic and differentiation pathways. Dysregulation of these pathways can contribute to chemotherapeutic drug resistance, proliferation of cancer initiating cells (CICs) and premature aging. This review will evaluate more recently described potential uses of MEK, PI3K, Akt and mTOR inhibitors in the proliferation of malignant cells, suppression of CICs, cellular senescence and prevention of aging. Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways play key roles in the regulation of normal and malignant cell growth. Inhibitors targeting these pathways have many potential uses from suppression of cancer, proliferative diseases as well as aging.

Additional Information

Publication

Other

Oncotarget; 2:3 p. 135-164

Language: English

Date: 2011

Keywords

Combination Therapy, Senescence, Aging, Targeted Therapy, Akt, Raf, Drug Resistance, mTOR, PI3K, Cancer Stem Cells

Email this document to